The CODIACS-QoL trial: Ineffective but cost-effective? - 27/06/21
Doi : 10.1016/j.genhosppsych.2021.05.002
Roy C. Ziegelstein a, ⁎ 
, Brett D. Thombs b, c, d, e, f, g, h
, Brett D. Thombs b, c, d, e, f, g, h a Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA
b Lady Davis Institute for Medical Research, Jewish General Hospital, Montréal, Québec, Canada
c Department of Psychiatry, McGill University, Montréal, Québec, Canada
d Department of Epidemiology, Biostatistics and Occupational Health, McGill University, Montréal, Québec, Canada
e Department of Medicine, McGill University, Montréal, Québec, Canada
f Department of Psychology, McGill University, Montréal, Québec, Canada
g Department of Educational and Counselling Psychology, McGill University, Montréal, Québec, Canada
h Department of Biomedical Ethics Unit, McGill University, Montréal, Québec, Canada
⁎Corresponding author at: Department of Medicine, B-1-North, Johns Hopkins Bayview Medical Center, 4940 Eastern Avenue, Baltimore, MD 21224-2780, USA.Department of MedicineJohns Hopkins Bayview Medical CenterB-1-North4940 Eastern AvenueBaltimoreMD21224-2780USA
Le texte complet de cet article est disponible en PDF.
Plan
© 2021
Publié par Elsevier Masson SAS.
Vol 71
P. 140-141 - juillet 2021 Retour au numéro
Article précédent
- Due to their anti-inflammatory, antioxidant and neurotrophic properties, second-generation antipsychotics are suitable in patients with schizophrenia and COVID-19
- Hiram Tendilla-Beltrán, Gonzalo Flores
- Generalized anxiety, depression and posttraumatic stress disorder in a national sample of U.S. internal medicine physicians during the COVID-19 pandemic
- Jeffrey Sonis, Donald E. Pathman, Susan Read, Bradley N. Gaynes, Courtney Canter, Patrick Curran, Thomas Miller
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?